HOME >> MEDICINE >> NEWS
Large tularemia vaccine contracts among new NIAID biodefense awards

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has recently made several dozen awards to further strengthen the nation's biodefense and emerging disease research capabilities. The new awards include grants totaling approximately $87 million for the construction of four biosafety level-3 (BSL-3) laboratories as well as two five-year contracts totaling approximately $60 million to support the development of a vaccine against tularemia, a potential agent of bioterror.

"Devising medical countermeasures against biological threats, whether they arise naturally or are the result of deliberate human action, is a top priority for NIAID," says NIAID Director Anthony S. Fauci, M.D. "These new awards support research needed to better understand and defend against disease-causing microbes and provide funds to construct facilities where such research can be performed safely."

Regional Biocontainment Laboratories

The four new labs will join nine other NIAID-funded BSL-3 labs in the Institute's Regional Biocontainment Laboratory (RBL) program. In 2002, a panel of experts convened to provide guidance to NIAID on its biodefense agenda cited insufficient BSL-3 and BSL-4 space as a major barrier to research progress. As part of its response, NIAID established the RBL program to fund the design, construction and commissioning of state-of-the-art BSL-3 labs at sites spanning the country. The institutions receiving the new awards and the principal investigators are as follows:

  • Charles Bailey, Ph.D., George Mason University, Manassas, VA
  • Sawkat Anwer, D.M.V.H., Ph.D., Tufts University, North Grafton, MA
  • Nancy Martin, Ph.D., University of Louisville, KY
  • James Gaines, Ph.D., University of Hawaii at Manoa

More information about NIAID's biocontainment facility construction program and a map of the previously awarded sites is at <
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
3-Oct-2005


Page: 1 2 3

Related medicine news :

1. Largest ever grant for University of Copenhagenhagen
2. Large subset of learning disabled children can be quickly identified by new diagnostic device
3. Large collaborative effort provides first publicly available genetic data for Parkinsons research
4. Largest review of Loeys-Dietz Syndrome to date
5. Large-scale cross-platform study of research microarrays uncovers high concordance across platforms
6. Large NCI grant will test the effect of Tibetan yoga on women with breast cancer
7. Large prospective study examines colon cancer risk in women
8. Large study shows low-fat diet has little effect on reducing risk of breast cancer
9. Largest study of in-hospital cardiac arrest suggests how to improve outcomes for children and adults
10. Large-scale study proves volunteer operated defibrillators are life-savers
11. Largest survey on depression suggests higher prevalence in U.S., reports Mailman school

Post Your Comments:
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... 22, 2014 The Louis ... is dedicated to distribute health information technology innovation ... worldwide announced the development of six key guiding ... when receiving healthcare. These are an expansion of ... “providing care that is respectful of and responsive ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
(Date:10/22/2014)... 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) ... novel investigational drug for cancer, is designed for injection ... effects. Its oncology focus is on melanoma, breast cancer ... 2 trials of PV-10 as a therapy for metastatic ... atopic dermatitis and psoriasis. This summer, ...
(Date:10/22/2014)... , Oct. 22, 2014  Recently published clinical ... bolstered the already substantial database of evidence. This data ... of Stretta therapy for sufferers of refractory ... clinical evidence supporting Stretta therapy as a safe ... that make Stretta therapy available to nearly 50 million ...
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
Cached News: